Sotera Health Company (SHC)
NASDAQ: SHC · Real-Time Price · USD
16.75
+0.19 (1.15%)
At close: Dec 5, 2025, 4:00 PM EST
16.54
-0.21 (-1.25%)
After-hours: Dec 5, 2025, 5:32 PM EST
Sotera Health Company Stock Forecast
Stock Price Forecast
According to 5 professional analysts, the 12-month price target for Sotera Health Company stock ranges from a low of $16 to a high of $20. The average analyst price target of $17.8 forecasts a 6.27% increase in the stock price over the next year.
Price Target: $17.80 (+6.27%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Sotera Health Company stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BMO Capital | BMO Capital | Buy Initiates $19 | Buy | Initiates | $19 | +13.43% | Nov 13, 2025 |
| JP Morgan | JP Morgan | Hold Maintains $14 → $16 | Hold | Maintains | $14 → $16 | -4.48% | Nov 5, 2025 |
| Barclays | Barclays | Buy Maintains $19 → $20 | Buy | Maintains | $19 → $20 | +19.40% | Nov 5, 2025 |
| Piper Sandler | Piper Sandler | Hold Maintains $15 → $17 | Hold | Maintains | $15 → $17 | +1.49% | Nov 5, 2025 |
| Barclays | Barclays | Buy Maintains $17 → $19 | Buy | Maintains | $17 → $19 | +13.43% | Oct 2, 2025 |
Financial Forecast
Revenue This Year
1.17B
from 1.10B
Increased by 6.41%
Revenue Next Year
1.24B
from 1.17B
Increased by 5.89%
EPS This Year
0.84
from 0.16
Increased by 438.76%
EPS Next Year
0.95
from 0.84
Increased by 12.90%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | 1.2B | 1.3B | ||
| Avg | 1.2B | 1.2B | ||
| Low | 1.1B | 1.2B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | 10.7% | 10.9% | ||
| Avg | 6.4% | 5.9% | ||
| Low | 3.1% | 1.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | 0.89 | 1.02 | ||
| Avg | 0.84 | 0.95 | ||
| Low | 0.81 | 0.90 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | 464.5% | 20.6% | ||
| Avg | 438.8% | 12.9% | ||
| Low | 418.8% | 6.7% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.